Advances in Endocrine Therapies 2005 Novel treatments targets & therapeutic potential 19th and 20th January 2005 - Workshop 18th January 2005 Kensington Marriott Hotel, London
**** CONFERENCE BROCHURE AVAILABLE NOW - REQUEST YOURS TODAY ****
In such a wide reaching industry, it is important to focus on key areas of progression. At this conference delegates will learn about new developments in significant areas of the market, from diabetes and obesity to cancer and hormone replacement therapies.
THEMES WILL INCLUDE: **New developments in diabetes - how can your company enter this rapidly growing & changing market? **Learn about new approaches to weight loss & emerging therapies for metabolic diseases **Advice on how your company can become an industry leader in the market for infertility drugs **Improve your clinical trials for osteoporosis & learn about the alternatives to HRT **Achieve more efficient insulin delivery - optimise your potential success **Benefit from the best practice case studies: Forteo; Passport; Somatostatin
KEY SPEAKERS **Dr. Anthony Beardsworth, Lead Physician, Primary Care, Eli Lilly **Dr. Monique Berwaer, Head, Metabolic Diseases, Johnson & Johnson **Caroline Turnbull, Armidex Brand Leader, AstraZeneca **Dr. Desmond Thompson, Senior Scientific Director, Merck **Dr. Milan Zdravkovic, International Medical Officer, NovoNordisk **Dr. Manfred Ganz, Director, Head of Medical Assessment Strategy and Business Development, Roche **Dr. Bharat Tewarie, Executive Vice President, Reproductive Health, Serono **Dr. Eric Tomlinson, Chief Executive Officer, Altea Therapeutics **Dr. George Merriam, Scientific Advisor, Theratechnologies **Dr. Gerald Bernstein, Vice President, Medical Affairs, Generex Biotechnology **Dr. Alan Davis, European Medical Director, Kendle
------------------ WHO SHOULD ATTEND ------------------
**Vice President, Global Medical Endocrinology **Senior Vice President, Endocrine Business **Senior Medical Director, Endocrinology **Director, Endocrinology & Metabolism **Senior Director, Metabolic Diseases **Global Head, Diabetes & Clinical Research **Vice President, Diabetes **Vice President, Glucose Monitoring Systems **Vice President, Cardiovascular & Metabolism **Executive Vice President, Women's Health **Vice President, Reproductive Health
================================================================== This event will also feature: Pre-conference Interactive Workshop ================================================================== Glucose Sensing & Insulin Pumps Workshop leaders: Ian Tilly, Glucose Sensor Specialist, Medtronic MiniMed Uk & Ireland Susan Judge, Diabetes Specialist, Nurse & Education Co-ordinator.
Strategies for pricing and market access of innovative endocrine therapies Led by: Christian Schuler, Director Health Sciences Division, Simon-Kucher & Partners
--------------------- DELEGATE REGISTRATION ---------------------
Places at this event are strictly limited so BOOK YOUR PLACE NOW. To make a booking on this event, please contact me via phone or email. Book early to secure a place.
- PRICING -
Attend the: 2 Day conference with interactive workshop - ONLY GBP1600 plus VAT 2 Day conference - ONLY GBP1299 plus VAT Workshop only - ONLY GBP650 plus VAT
- BOOKINGS -
Booking is easy, simply contact me:
Joe Stone Account Manager - Conference Division Visiongain B2B Conferences Tel. +44(0)20 8767 6711 Fax. +44(0)20 8767 5001 mailto:joe.stone@visiongain.com
B2B Conferences is part of the Visiongain Group
**** FULL CONFERENCE AGENDA BELOW ****
=================================== PRE-CONFERENCE INTERACTIVE WORKSHOP Tuesday 18th January 2005 =================================== Glucose sensing & insulin pumps: optimise diabetes care & analyse pump therapy
Led by: Ian Tilly, Glucose Sensor Specialist & Susan Judge, Diabetes Specialist, Nurse & Education Co-ordinator, Medronic MiniMed UK & Ireland
Main topics of discussion: . Validation of new treatment efficacy in improving glycaemic control. . Enhancing the value of clinical trials. . Features and benefits of insulin pump therapy. . Combining sensors & pumps - creating an artificial pancreas.
Strategies for pricing and market access of innovative endocrine therapies Led by: Christian Schuler, Director Health Sciences Division, Simon-Kucher & Partners
Strategies for Pricing and Market Access of Innovative Endocrine Therapies . Challenges within the endocrine market environment . P&R Environment for innovative endocrine therapies . Key learnings from recent product launches . The concept of value based pricing . Pricing techniques
=================================== Day One Wednesday 19th January 2005 ===================================
09:00 Registration and coffee
09:30 Opening remarks from the chair
09:40 An Overview of the Industry Dr. Ray Scraggs, Head Consultant at visiongain, will introduce questionnaires which give you the chance to make comments on the Endocrine Industry. The findings will be discussed at the end of the day in a panel session.
NEW DEVELOPMENTS IN DIABETES
09:50 The Future of the Diabetes Market: What are the Possibilities for Your Company? . How to rise to the challenge for advanced and effective treatment . Impaired metabolism: how to cope with complications . Tactics for novel target discovery . Strategies for genomics based drug discovery . Tips on improving diabetes care - decrease complications and gain metabolic control . How to avoid microvascular complications . Different approaches to post infection therapies Dr. Manfred Ganz, Director, Head of Medical Assessment Strategy and Business Development Global Diabetes Care Roche Diagnostics GmbH
10:30 CASE STUDY: 11 bHSD1 - A Novel Target in the treatment of Diabetes & Metablic Symdrome . The potential of selective 11 bHSD1 inhibition in the treatment of diabetes and associated complications . The need for a better understanding of the endocrine function of adipose tissue . Cortisol induced insulin resistance in man . HSD1 and metabolic syndrome: what are the possibilities for your company? . Effect of selective HSD1 inhibition in diabetic rodents: analysis of results . The importance of 11beta-HSD1 in the development of metabolic syndrome - examination of data from studies of obese rodents Dr. Monique Berwaer, Head, Metabolic Diseases Johnson & Johnson
11:10 Morning Coffee
11:30 CASE STUDY: Incretin Mimetics - GLP-1 and Liraglutide . Mechanism of action: increasing insulin secretion; reducing glucagon production; delaying gastric emptying . What are the potential applications? . Possible multiple benefits including weight loss vs drawbacks of delivery by injection . Analysis of results of preclinical testing . Potential for sustained action - improving patient care Dr. Milan Zdravkovic, International Medical Officer Novo Nordisk
12:10 Innovations in Insulin Delivery: Possibilities for New Technologies . What will be the future of the insulin pill? - replacing first phase insulin response . Recent advances in insulin pump therapy - analysis of new possibilities & assessment of options . The impact of oral insulin spray on the market . Updates on FDA approval for inhaled insulin: overcoming long term effects Dr. Gerald Bernstein, Vice President, Medical Affairs Generex Biotechnology
12:50 Lunch
14:00 CASE STUDY: Passport - The Potential for Transdermal Insulin Delivery . Mechanism of action: a sonic applicator deploying . ultrasound & introducing drug molecules through the skin Added benefits of combined skin patch and insulin pill . Increasing administration length: new development of a 24 hour patch . Advantages over alternatives - achieve steady and accurate delivery of your diabetes drugs . Improve patient compliance - a non-invasive, pain and hassle free treatment . Market potential - a cost-effective, efficient treatment without troublesome side-effects Dr. Eric Tomlinson, Chief Executive Officer Altea Therapeutics
NOVEL TREATMENTS IN THE OBESITY MARKET
14:40 New Approaches to Weight Loss Drugs: Responding to Gaps in the Obesity Market . Current drugs and their limitations: lessons to be learnt from the past . How can body weight be regulated and modified? . New approaches for discovering novel targets for the treatment of obesity Jon Arch, Professorial Research Fellow, Deputy Director of Metabolic Research University of Buckingham
15:20 Afternoon Tea
THE ENDOCRINE TREATMENT OF BREAST CANCER
15:40 CASE STUDY: Armidex - the Future of Treatment & Prevention of Breast Cancer . The first aromatase inhibitor to be approved - effect on your market . Current market for breast cancer drugs - where can you capture a share? . Developments in endocrine agents: steps towards the goal of breast cancer prevention . Comparison of aromatase inhibitors with tamoxifen - how long before tamoxifen is obsolete? . Analysis of results of recent clinical studies Caroline Turnbull, Arimidex Brand Leader AstraZeneca
16:20 Questions and Discussion
16:30 Summation of day one from conference chair
16:40 Close of Day One
================================== Day Two Thursday 20th January 2005 ==================================
08:30 Registration and Coffee
09:00 Opening remarks from the Chair
DEVELOPMENTS IN GROWTH HORMONE THERAPIES
09:10 KEYNOTE SESSION
MINI SYMPOSIUM: GROWTH HORMONECLINICAL INSIGHTS & MECHANISMS With invited manufacturers of growth hormone and growth hormone secretagogues Led By: Dr. George Merriam Scientific Advisor, Professor of Medicine Theratechnologies, University of Washington
10:10 CASE STUDY: Somatostatin - Developments in the Treatment of Acromegaly . Mechanism of action of somatostatin analogues . The need to improve clinical management of patients . Addressing patient issues: appropriate dosing regimes & extended duration preparations . Defining the role of somatostatin analogues: checking & balancing hormones & growth . Advantages of multiple benefits: treating adverse clinical effects of acromegaly . SOM230: a new multiligand somatoststatin analogue - the possibilities for future treatments Dr. Herbert Schmid, Senior Research Investigator for Somatostatin Research Novartis
10:50 Morning Coffee
ENDOCRINOLOGY AND WOMEN'S HEALTH ISSUES
11:10 The Endocrinology Of Ageing . Ageing - the major driver in the endocrine industry: gain your share of the market . The underlying mechanisms responsible for reduction in strength, frequency and production of hormones . Future targets for age-related diseases: what are the opportunities for your company? Dr. Desmond Thompson, Senior Scientific Director Merck
11:50 Delivering Clinical Trials for Osteoporosis: Improve your Company's Studies . Clinical trial metrics & management: ensure your osteoporosis trials are efficient & cost effective . Tips for long & short term studies . Advice on recruiting & retaining trial subjects . How to select appropriate clinical endpoints for your osteoporosis trials . Safety assessments & regulatory requirements: how do they affect your studies? Dr. Alan Davies, European Medical Director Kendle
12:30 Lunch
14:00 CASE STUDY: Forteo - The First Bone Formation Agent in the Treatment of Osteoporosis . Mechanism of action: the use of recombinant human parathyroid hormone: the potential to replace depleted bone stores . Multiple benefits: forming new bone, increasing bone density and improving bone strength . Overcoming possible side effects - what can be done to improve patient care? . The proven success of Forteo: results from the fracture prevention trial . Launch in India - tracking the success Dr. Anthony Beardsworth, Lead Physician, Primary Care Eli Lilly
14:40 CASE STUDY: Microencapsulated r-FSH - Novel Treatments for Infertility . The growing market for the treatment of infertility - tips for market share . Learn from the experts - how Serono became market leaders for the treatment of infertility with Gonal-F . Gonal-f(R) RFF Pen: the first and only prefilled and ready-to-use multi-dose FSH in the US . Benefits of rFSH over urinary products - consistent potency & less contaminants . Analysis and updates of recent clinical trials . Future targets for the treatment of infertility Dr. Bharat Tewarie, Executive Vice-President, Reproductive Health Serono
15:20 Afternoon Tea
RECENT ADVANCES IN HYPERTENSION
16:00 CASE STUDY: SPP100 (Aliskiren) - A Novel Treatment for Hypertension & Related Conditions . A new mode of action for the treatment of hypertension & end organ damage . Analysis of results of recent clinical trials & studies: Aliskiren Vs Irbesartan . New technical achievements: producing a commercially viable manufacturing process . Possibilites for multiple treatment benefits Dr. Hans Brunner, Medical Advisor Speedel
16:40 DISCUSSION: Attendees Perspective Presentation and discussion of the questionnaire results led by Dr. Ray Scraggs. This will involve some freeform discussion & the opportunity to engage in knowledge sharing with fellow professionals.
17:00 Chairman summation and close of conference
Terms & Conditions NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below. Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.
Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.